Related Experiment Video
Updated: Mar 19, 2026
10:41
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
Published on: February 17, 2017
8.5K
Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site
Nataliya Bohdan1, Salvador Espín1, Sonia Águila1
1Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain.
Plos One
|June 21, 2016
Summary
Heparanase directly interacts with and activates antithrombin, the primary anticoagulant, through a non-enzymatic mechanism. This finding reveals a novel role for heparanase in regulating blood coagulation and anticoagulation processes.
Area of Science:
- Biochemistry
- Molecular Biology
- Hemostasis
Background:
- Heparanase is an endoglycosidase involved in tissue repair and metastasis.
- It can influence the hemostatic system non-enzymatically, promoting a procoagulant state.
- Its interaction with anticoagulants like antithrombin is not fully understood.
Purpose of the Study:
- To investigate the effect of heparanase on heparin's activation of antithrombin.
- To determine if heparanase directly interacts with antithrombin.
- To elucidate the mechanism of heparanase-antithrombin interaction and its functional consequences.
Main Methods:
- Studied the interaction between heparanase and antithrombin using biochemical assays.
- Utilized antithrombin mutants to identify the binding site.
- Employed intrinsic fluorescence analysis to assess conformational changes.
Main Results:
- Heparanase, but not proheparanase, directly interacted with antithrombin non-covalently.
- This interaction activated antithrombin, enhancing Factor Xa inhibition, suggesting allosteric activation.
- Heparanase bound to the heparin-binding site of antithrombin, confirmed by mutant studies.
Conclusions:
- Heparanase exerts a non-enzymatic function by interacting with and activating antithrombin's inhibitory function.
- This interaction may play a role in regulating anticoagulation under physiological conditions.
- Heparanase's interaction with antithrombin is distinct from its enzymatic activity and involves its heparin-binding site.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:29Venous Thrombosis III: Interprofessional Care
455
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
455
01:30Drug Binding to Blood Components
629
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
629
01:20Extrinsic and Intrinsic Pathways of Hemostasis
14.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.9K
01:16Clot Retraction and Fibrinolysis
10.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.0K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K